AstraZeneca and Bristol Myers Squibb are Playing Merger Poker! Will a new $400 Billion Pharmaceutical Giant Emerge?
Reading Time: 3 minutes
Historical dimension: The merger of AstraZeneca and Bristol Myers Squibb would create a pharmaceutical giant valued at $400 billion Complementary portfolios: The merger would strengthen AstraZeneca's presence in the US and consolidate leading cancer and cardiovascular medications Significant hurdles: In addition to the early stage of talks, strict antitrust authorities are likely to scrutinize the mega-deal The consolidation in the global pharmaceutical industry is reaching a new dimension. Preliminary talks about a merger between...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
